NCT03873870View on ClinicalTrials.gov

68Ga-DOTATATE PET for Management of Neuroendocrine Tumors

NACompletedINTERVENTIONAL
Enrollment

1,916

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Neuroendocrine Tumors
Interventions
DIAGNOSTIC_TEST

68Ga -DOTATATE PET scans

PET scan using 68Ga-DOTATATE contrast

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT03873870 - 68Ga-DOTATATE PET for Management of Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter